Librax (5 mg chlordiazepoxide HCl and 2.5 mg clidinium bromide) capsules, 100-count bottle, Rx Only, Manufactured in Canada by: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7 Canada; Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807, NDC 0187-4100-10.

Failed Impurities/Degradation Specifications

Recall #: D-1034-2016
Affected scope: 6,321 bottles
Initiated: April 18, 2015

Compiled from official public sources by the publisher. · Updated September 2026

Valeant Pharmaceuticals North America LLC recalled Librax (5 mg chlordiazepoxide HCl and 2.5 mg clidinium bromide) capsules, 100-count bottl… - a low-severity action.

Librax (5 mg chlordiazepoxide HCl and 2.5 mg clidinium bromide) capsules, 100-count bottl… was recalled by Valeant Pharmaceuticals North America LLC in June 22, 2016. Reason: Failed Impurities/Degradation Specifications. Check the official notice for the remedy. Verify recall #D-1034-2016 with the FDA Drug before acting.

The recall

Valeant Pharmaceuticals North America LLC issued this low-severity FDA Drug recall-Failed Impurities/Degradation Specifications.

Low
severity level: Class III
classification: June 22, 2016
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1034-2016 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 1 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Librax (5 mg chlordiazepoxide HCl and 2.5 mg clidinium bromide) capsules, 100-count bottle, Rx Only, Manufactured in Canada by: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7 Canada; Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807, NDC 0187-4100-10.

Reason for recall

Failed Impurities/Degradation Specifications

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Low (Class III)
Status	Terminated
Recall number	D-1034-2016
Date reported	June 22, 2016
Date initiated	April 18, 2015
Recalling firm	Valeant Pharmaceuticals North America LLC
Firm location	Bridgewater, NJ
Affected scope	6,321 bottles
Distribution	Nationwide and Puerto Rico

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-1034-2016) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Failed Impurities/Degradation Specifications

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on June 22, 2016. Severity: Low. Recall number: D-1034-2016.

Where was the recalled product distributed? ▼

Distribution: Nationwide and Puerto Rico.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Low), closest by report date among other firms and states.

Doxycycline, USP Capsules 40 mg, Packaged… 2016-06-22 Pramipexole Dihydrochloride Extended Rele… 2016-06-22 Ariol is an automated scanning microscope… 2016-06-22 Hyoscyamine Sulfate Sublingual Tablets, 0… 2016-06-29

Similar Children & Baby Products · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Following an Additional Child Fatality, I… 2016-06-28 VP-CH-PNV Prenatal/Postnatal capsules, pr… 2016-06-29 ITRACONAZOLE 0.2%/MUPIROCIN 0.2%/TRIAMCIN… 2016-06-15 Auldey Toys Recalls Sky Rover Toys Due to… 2016-06-10

Compare this recall with CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per … → · All Children & Baby Products recalls

This recall: FDA Drug, reported June 22, 2016. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026